REVA Medical, Inc. - FORM 8-K - EX-99.1 - October 31, 2017

Attached files

file filename
8-K - 8-K - REVA Medical, Inc.rva-8k_20171031.htm
EX-99.1 2 rva-ex991_6.htm EX-99.1 rva-ex991_6.pptx.htm

Slide 1

TCT 332: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 24 Month Outcomes Fantom II Clinical Trial Investigators Exhibit 99.1

REVA Medical, Inc. Reports